Loading
Andrés Cervantes is a gastrointestinal oncologist and was ESMO President for 2023-2024.
Andrés Cervantes is Professor of Medicine at the University of Valencia and Head of Medical Oncology at the INCLIVA Biomedical Research Institute and Hospital Clínico Universitario de Valencia, and served as President of the European Society for Medical Oncology (ESMO) for 2023-2024. A gastrointestinal oncologist specialising in colorectal cancer, he is best known for guideline work. He led the ESMO Clinical Practice Guidelines on metastatic colorectal cancer in Annals of Oncology, in their 2014 and 2023 editions, and co-authored the 2012 ESMO consensus guidelines on a personalised approach to colon and rectal cancer. His publications are listed on PubMed.
This is the European standard the UK and NHS page for colorectal cancer is compared against; NICE NG151 covers the same ground for England with a narrower set of funded drugs.
The analysis that put 'left-sided, RAS and BRAF wild-type' into every guideline as the anti-EGFR population, and made an anatomical fact into a treatment-selection biomarker.
The document behind the MRI-first rectal cancer pathway used across Europe and the UK; the total neoadjuvant therapy trials (RAPIDO, PRODIGE 23, OPRA) that came after it are the main reason an update was needed.
Shares Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, European Society for Medical Oncology (ESMO), Colorectal cancer.
Shares Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Colorectal cancer.
Shares Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Colorectal cancer.
Shares Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, European Society for Medical Oncology (ESMO), Colorectal cancer.
Shares Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Colorectal cancer.
Shares INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia, Colorectal cancer.
Shares Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, European Society for Medical Oncology (ESMO).
Shares INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia, Colorectal cancer.